Dynamic medical professional and leader with extensive experience in regulatory compliance and clinical trial management at Eli Lilly and Company. Demonstrated success in strategic planning and stakeholder engagement, resulting in significant product portfolio expansions. Skilled in risk management and team leadership, promoting a culture of excellence in clinical operations. Comprehensive knowledge of market trends and corporate finance enhances ability to execute effective business strategies and oversee financial performance.
A.K Shrivastava, Sunaina Shrivastava, Anu Sinha, 2
India business transition for diabetes, 2021 Third party management from regulatory perspective for India neighbouring countries, 2021 Lilly global project as part clinical development transition to IQVIA, 2021 Six sigma efforts on New Product Planning, 2011 Six sigma efforts on Portfolio Planning, 2011 Setting the Regional CSM team for AMERIT, 2011 Site Activation Team for AMERIT, 2011 Global Site Monitoring Process (GSMP) from India, 2011 Six Sigma Kaizen Project, 2008
Director-Regulatory Affairs & Pharmacovigilance, Eli Lilly and Company, 03/01/18, Leading the regulatory affairs and pharmacovigilance responsibility for India & sub region., Involved in India affiliate strategy for new product portfolio, planning the pipeline products, clinical research/operations strategy for India and sub region., Regulatory alliance management for diabetes portfolio with local companies., Third party alliance management and governance from regulatory perspective., Core member of India industry groups for policy shaping and related regulatory interactions.